16:58 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Tonix stops Phase III of PTSD candidate on lack of separation from placebo

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) said it will stop the Phase III HONOR trial of Tonmya (Sublingual TNX-102) to treat military-related post-traumatic stress disorder (PTSD) after the candidate showed "inadequate separation" from placebo at an...
03:04 , Jun 30, 2018 |  BioCentury  |  Finance

Eyes on launches

The annual summer slowdown isn’t restricted to just the stock market this year, as the clinical catalyst calendar also appears to be on holiday in 3Q18. Buysiders are therefore turning their attention to a spate...
17:17 , May 11, 2018 |  BC Week In Review  |  Financial News

Neurana closes $60M series A

Neurana Pharmaceuticals Inc. (San Diego, Calif.) closed a $60 million series A round led by Sofinnova Ventures. Also participating were New Leaf Venture Partners, H.I.G. BioHealth Partners, Longitude Capital Management and MagnaSci Ventures. Neurana has...
21:46 , May 7, 2018 |  BC Extra  |  Financial News

Neurana closes $60M series A

Neurana Pharmaceuticals Inc. (San Diego, Calif.) closed a $60 million series A round led by Sofinnova Ventures. Also participating were New Leaf Venture Partners, H.I.G. BioHealth Partners, Longitude Capital Management and MagnaSci Ventures. Neurana has...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
21:48 , Apr 20, 2017 |  BC Week In Review  |  Clinical News

TNX-102 SL: Ph III HONOR started

Tonix began the double-blind, placebo-controlled, U.S. Phase III HONOR trial to evaluate 5.6 mg sublingual TNX-102 daily at bedtime for 12 weeks in about 550 patients. An IDMC will perform an interim analysis when efficacy...
21:37 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

TNX-102 SL: Ph II AtEase data

The double-blind, U.S Phase II AtEase trial in 231 patients with military-related PTSD showed that once-daily 2.8 mg sublingual TNX-102 SL given at bedtime missed the primary endpoint of improving CAPS-5 total symptom severity score...
22:21 , Dec 21, 2016 |  BC Week In Review  |  Clinical News

TNX-102 SL regulatory update

FDA granted breakthrough therapy designation to TNX-102 SL from Tonix to treat post-traumatic stress disorder (PTSD). In 1Q17, the company plans to start the Phase III HONOR trial of the sublingual formulation of cyclobenzaprine, a...
07:00 , Sep 12, 2016 |  BC Week In Review  |  Clinical News

Tonmya: Phase III data

Top-line data from the double-blind, U.S. Phase III AFFIRM trial in 519 fibromyalgia patients showed that once-daily 2.8 mg sublingual TNX-102 missed the primary endpoint of a greater proportion of patients with a >=30% reduction...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

Tonmya: Phase III started

Tonix began the double-blind, placebo-controlled, U.S. Phase III RE-AFFIRM trial to evaluate 2.8 mg TNX-102 SL once daily at bedtime for 12 weeks in about 500 patients. The company expects data from the Phase III...